{"id":"W4410463538","doi":"10.1016/j.esmoop.2025.104671","title":"117P PIK3CA mutational status concordance between plasma and tumor in HER2+ advanced breast cancer (ABC) patients (pts) of ALPHABET (GEICAM/2017-01_IBCSG 62-20_BIG 18-04) trial","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Ipsen; Universitat de València; PharmaMar; Astellas Pharma; Seagen; Sociedad Española de Oncología Médica; BeiGene; Mersana Therapeutics; AstraZeneca España; Menarini Silicon Biosystems; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Carrick Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Dana-Farber Cancer Institute; McGill University; Merck KGaA; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer","keywords":"Concordance; Breast cancer; Oncology; Internal medicine; Medicine; Alphabet; Cancer; HER2 negative; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002674273,0.000348085,0.0009703102,0.0002172522,0.0001083296,0.00004403172,0.0003889852,0.0001067659,0.0004271198],"category_scores_gemma":[0.0001633791,0.0003296069,0.00007768698,0.0005087036,0.0003251541,0.0005205505,0.0002953,0.0003422768,0.00001087272],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004430183,"about_ca_system_score_gemma":0.0009644635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003176204,"about_ca_topic_score_gemma":0.0009846344,"domain_scores_codex":[0.9974455,0.0001191609,0.000791996,0.0006538782,0.0004528564,0.0005366717],"domain_scores_gemma":[0.998409,0.000269011,0.0004019415,0.0004259029,0.0002916349,0.0002024897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05596069,0.0007762485,0.757882,0.0002768706,0.0004058592,0.00004144455,0.0008078187,0.0001689115,0.0002845762,0.000427676,0.0007624677,0.1822055],"study_design_scores_gemma":[0.0926513,0.0006286284,0.8898035,0.0008204037,0.0001060408,0.00001101495,0.0002494509,0.00006262449,0.001154369,0.0007049475,0.01350026,0.0003074656],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916348,0.000357389,0.00009135251,0.001029505,0.0005484045,0.002456511,0.001014666,0.00003657185,0.002830727],"genre_scores_gemma":[0.9950302,0.00008901463,0.002230906,0.0005781393,0.0001877319,0.0004716934,0.0002145196,0.00004646918,0.001151384],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.181898,"threshold_uncertainty_score":0.9999156,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02253178367579364,"score_gpt":0.3512807230497896,"score_spread":0.328748939373996,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}